You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

75 Results
Guidelines and Advice
Status: Current
ID: MCC
Jun 2006
Guidelines and Advice
Status: Archived
ID: 20-1
Aug 2006
Guidelines and Advice
Status: Education and Information
ID: 1-24 Version 2
Version: 2
May 2006
Guidelines and Advice
Status: Archived
ID: CED 3
Jan 2006
Guidelines and Advice
Status: Archived
ID: CED 2
Version: 2
Jan 2006
Guidelines and Advice
Status: Archived
ID: 13-8
Oct 2006
Guidelines and Advice
Status: Archived
ID: HPVTest
Apr 2006
Guidelines and Advice
Status: Current
ID: GL-C50-03
Apr 2006
Statistical Reports
May 2006
Regimen
Cancer Type:
Gastrointestinal, 
Colorectal
Show More Show more tags
, Show Less Show fewer tags
Intent: Palliative
Funding:
Exceptional Access Program
    fruquintinib - For the treatment of metastatic colorectal cancer according to specific criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
fruquintinib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2026
Regimen
Cancer Type:
Central Nervous System
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative, Palliative
Funding:
Exceptional Access Program
    vorasidenib - For the treatment of Grade 2 astrocytoma or oligodendroglioma in patients with a susceptible IDH1 mutation or IDH2 mutation following surgery, based on criteria
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
vorasidenib
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Mar 2026
Drug
Other Name(s): Zoladex® , Zoladex® LA
Quick Link(s):
Drug Monograph, Patient Info Sheet
Mar 2026

Pages